Alzheimer's disease (AD) is a disorder characterised by a progressive deterioration in memory and other cognitive functions. Glycogen synthase kinase 3 beta (GSK3␤) phosphorylates the microtubule associated protein tau at sites that are aberrantly phosphorylated in AD. GSK3␤ binds to presenilin 1 and plays a role in wnt and insulin signalling cascades, both of which have been proposed to be linked to AD. Moreover GSK3␤ activity may be altered in AD brain. These observations suggest a central role for GSK3␤ in AD and led us to investigate GSK3␤ as a candidate gene for AD. We sought to identify sequence variations in the gene and its promoter, as these could have an effect on activity and expression leading to abnormal function. Sequencing over 3000 bp of the GSK3␤ putative promoter revealed there to be five sequence variations, two of which were common (Ͼ10%). However on further examination none of these, either alone or in synergy, had any association with late onset AD. Stratification of the data by APOE ⑀4 status also produced no significant association. Sequencing of the GSK3␤ coding region revealed no variations. This would suggest that the aberrant phosphorylation of tau by GSK3␤ in AD is not due to sequence variations in the gene or its promoter. Molecular Psychiatry (2001) 6, 320-324.
Late onset Alzheimer's disease (AD) is the most common form of progressive neurodegenerative dementia afflicting 5-10% of the population aged over 65 years. 1 AD is characterised by two major neuropathological features, neuritic plaques and neurofibrillary tangles (NFT). NFT are intraneuronal inclusions of paired helical filaments (PHF), mostly comprised of highly phosphorylated microtubule associated protein tau. Tau promotes microtubule (MT) assemble in vitro 2 and stabilises MT in vivo 3 and it is thought that phosphorylation inhibits these processes and leads to continued PHF formation. Glycogen synthase kinase 3 beta (GSK3␤) has been shown to phosphorylate tau in vitro, in cells and in neurons at sites that are phosphorylated in PHF. [4] [5] [6] Several groups 7, 8 have shown that there is an increase in GSK3␤ levels in AD brain and that it is found to be associated with PHF. 7, 9 GSK3␤ also binds to the presenilin 1 protein, 10 it is a critical intermediate in the wnt signalling pathway suggested to be altered in AD 11 and in the insulin signalling cascade, also possibly altered in AD. 12 GSK3␤ is furthermore central to a number of putative pathological pathways in AD, positioning it as a very strong candidate gene. GSK3␤ is a proline directed ser/thr kinase that was initially identified as phosphorylating and inactivating glycogen synthase 13 and has been mapped to chromosome 3q13.3.
14 It is involved in a variety of signalling pathways affecting cell fate determination, 15 oncogenesis and metabolism. 16 We hypothesised that as GSK3␤ seems to play such an important role in cells it is unlikely that the gene itself is in some way defective in AD, but that a subtle variation in the coding or regulatory region may have an influence later in life.
Recent studies demonstrated that expression of GSK3␤ mRNA levels varies in different cells 17 suggesting that GSK3␤ has diverse transcriptional regulators. Lau et al 18 identified a number of regulatory elements; nt −1421 to −1363 may contain a repressor element, nt −427 to −384 may contain a cis-acting activating element and nt −171 to +29 contains an essential promoter element. They also established the presence of putative transcription factor CP2 binding sites at nt −1292 and nt +10. CP2 has been shown to interact with Fe65, a neuronal specific protein that itself interacts with amyloid precursor protein. 19 We therefore sought to sequence the promoter and the exonic sequence of GSK3␤ in a series of AD cases and controls to identify polymorphisms and then investigate these in AD.
We systematically sequenced 3029 bp upstream of the start codon of the GSK3␤ promoter. This was carried out for 30 controls and 30 AD samples. Five single nucleotide polymorphisms (SNPs) were detected. We identified two common SNPs at positions −1727 A/T and −50 C/T with rare allele frequencies in controls of 17% and 35% respectively. We also identified three rare SNPs at positions −1293 C/A, −620 T/A and +409 G/A with rare allele frequencies in controls of less than 1% (see Table 1 ). Only the +409 G/A polymorphism is transcribed, all other SNPs are in the untranscribed region. None of the SNPs fall into any putative transcription factor binding sites previously described, 18 however the rare −620 T/A SNP is only one base pair away. We examined each SNP in a larger sample population of ADs and controls to determine whether these alterations were potential disease-related or non pathogenic. Statistical analysis showed that all of the polymorphisms examined were in Hardy-Weinberg equi- 
Association statistics of alleles
librium. When comparing ADs to controls no statistically significant association of any SNPs was found for individual alleles and genotypes (see Table  1 ). Stratification by gender did not produce significant association for the two commonest SNPs. As it has been suggested that the clinical diagnosis of 'possible' AD and 'probable' AD are significantly different, 20 a further constraint of probable only AD was performed; again no significant differences were observed. Statistical analysis showed there to be a highly significant association between APOE ⑀4 allele frequency and AD (0.30) vs controls (0.11) (P = Ͻ10 −7 (OR = 3.42 (2.31-5.05)). However neither the −1727 A/T nor −50 C/T polymorphisms had any synergistic effect with the APOE ⑀4 allele and risk for AD, with P = 0.14 and P = 0.56 respectively. Haplotype analysis of the two common SNPs, −1727 A/T and −50 C/T, showed that these were in strong linkage disequilibrium (dЈ = 0.48, df = 3, P Ͻ 10 −7 ), however the haplotype was also not associated with AD.
Furthermore we systematically sequenced the entire coding sequence of the GSK3␤ gene to detect SNPs. This was carried out for 18 controls and 18 AD samples. Our analysis detected no sequence variations in AD or control cases.
To ensure that our analyses were specific to GSK3␤ and its promoter we performed radiation hybrid mapping 21 (data not shown) using several primer pairs. This revealed linkage of our PCR fragments to chromosome 3q13.3 with LOD scores of greater than 10, therefore confirming the specificity of our investigation. No other chromosomal location showed any significant linkage.
In this study we have investigated the frequency of
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SNPs in the GSK3␤ gene and its promoter and analysed their possible involvement in AD. None of the SNPs identified were localised in putative transcription factor binding sites, however the identification of such consensus sites is imprecise and ultimately functional studies are required. Statistical analysis showed there to be no significant association between any of the detected SNPs and AD when analysing the samples, even when stratified by sex, clinical diagnosis and APOE ⑀4 status. However, control populations are an intrinsic problem in AD genetic studies and this is as true for the control group we used and as for those used in other studies. We included only controls with no evidence of cognitive impairment (MMSE Ͼ 25) but it remains possible that we included a few individuals in the early, perhaps presymptomatic, stages of dementia. However it is unlikely that this would have affected our results. As we have investigated effectively 120 chromosomes for the promoter and 72 chromosomes for the GSK3␤ gene, we are confident that we have detected all common SNPs present in these regions in the Caucasian population. The power for detecting SNPs with frequencies of 10% is Ͼ99.9% for the 'promoter' samples and Ͼ99% for the 'coding' sample. The power for detecting SNPs with frequencies of 5% is slightly less at Ͼ95% and 95% for 'promoter' and 'coding' samples respectively. These power calculations are based on the number of chromosomes examined. The number of SNPs detected in the promoter region, one every 600 bp, is consistent with recent reports on SNP frequencies in non-repetitive, noncoding regions. 22 It is also not surprising that the GSK3␤ coding region was found to be non-polymorphic as the mutation rate in coding regions is around one every 2000 bp; 22 the GSK3␤ coding region is less than 1400 bp in length. The changes of GSK3␤ levels seen in AD, which are probably very relevant to the pathogenesis of AD, are not due to polymorphic variation in the GSK3␤ gene but possibly are a consequence of disruption of the wnt signalling pathway, which normally inhibits GSK3␤ activity. This could be due to polymorphism in a gene upstream of GSK3␤ in this signalling pathway.
Methods

Subjects
All subjects used were Caucasians. The test samples consisted of: 203 community-based late onset AD cases over the age of 60 years (mean age 82.4 (SD = 6.7)) who fulfilled the NINCDS-ADRDA criteria 20 for 'probable' (67%) and 'possible' (33%) AD, recruited from the Camberwell Dementia Case Register; 23 
PCR and sequencing analysis
We amplified 3 kb of the GSK3␤ promoter upstream of the start codon from lymphocyte derived genomic DNA as well as the complete coding region from brain derived cDNA. Primers (MWG-Biotech, UK) used are described in Table 2 . PCR reactions were performed in a final volume of 40 l containing 50 ng DNA, 0.3 M each primer and 1 U Taq DNA polymerase (Hybaid, UK). The PCR consisted of 35 cycles of 45 s at 94°C, 45 s at 50-60°C and 45 s at 72°C, preceded by 5 min at 95°C and followed by 10 min at 72°C. Products for sequencing were then purified using the Hybaid DNA purification Kit II (Hybaid). Thirty controls and 30 AD samples were sequenced for the promoter and 18 controls and 18 AD samples were sequenced for the coding region of GSK3␤. PCR products were sequenced in both directions using the Big Dye Terminator sequencing kit (Perkin Elmer, UK) and relevant PCR primers. Sequencing was performed on an ABI377 automated sequencer. The sequence data were reanalysed by the Phred program, 24, 25 assembled by the Phrap program, possible polymorphic bases identified by the PolyPhred program 26 and traces viewed using the program Consed. 27 Possible SNPs detected by sequencing were further investigated by restriction enzyme fragment (RFLP) analysis in larger cohorts of AD and control samples. Details of individual RFLP analyses are shown in Table 3 .
Statistics
Linkage disequilibrium was calculated using the EH program. 28 Values of DЈ, the normalised linkage disequilibrium statistic were calculated using published methods. 29 DЈ values are between 0 and 1 with larger values suggesting stronger linkage disequilibrium. Statcalc 30 was used for power calculations and for the comparison allelic distribution of SNPs between controls and ADs. Possible synergistic effects of the APOE ⑀4 allele and one or both of the common SNPs on disease outcome were considered using logistic regression, by means of the SPSS program.
